1. Home
  2. ACP vs ZVRA Comparison

ACP vs ZVRA Comparison

Compare ACP & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Income Credit Strategies Fund

ACP

abrdn Income Credit Strategies Fund

HOLD

Current Price

$5.33

Market Cap

703.9M

Sector

Finance

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$10.30

Market Cap

653.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACP
ZVRA
Founded
2010
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
703.9M
653.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
ACP
ZVRA
Price
$5.33
$10.30
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$23.00
AVG Volume (30 Days)
481.8K
1.3M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
17.79%
N/A
EPS Growth
N/A
159.21
EPS
N/A
0.60
Revenue
N/A
$106,470,000.00
Revenue This Year
N/A
$37.27
Revenue Next Year
N/A
$53.42
P/E Ratio
N/A
$17.44
Revenue Growth
N/A
350.91
52 Week Low
$4.99
$7.16
52 Week High
$5.99
$13.16

Technical Indicators

Market Signals
Indicator
ACP
ZVRA
Relative Strength Index (RSI) 47.53 48.41
Support Level $5.24 $8.30
Resistance Level $5.48 $11.07
Average True Range (ATR) 0.07 0.64
MACD -0.01 -0.05
Stochastic Oscillator 35.00 25.76

Price Performance

Historical Comparison
ACP
ZVRA

About ACP abrdn Income Credit Strategies Fund

abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: